Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6:69–80.
Wu H, Patterson CC, Zhang X, et al. Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021. Diabetes Res Clin Pract. 2022;185:109785.
RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test. Diabetes Care. 2018;41:1707–16.
RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care. 2018;41:1696–706.
Utzschneider KM, Tripputi MT, Kozedub A, et al. Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. Diabetes Res Clin Pract. 2021;178:108948.
Article CAS PubMed PubMed Central Google Scholar
TODAY Study Group, Bjornstad P, Drews KL, Caprio S, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385:416–26.
Article PubMed Central Google Scholar
Gurunathan U, Prasad HK, White S, Sangalalingam T, Krishnamoorthy N. Type 2 diabetes mellitus in adolescents from southern India - a single center experience. Indian Pediatr. 2021;58:176–7.
Article PubMed PubMed Central Google Scholar
Dave C, Agarwal N, Patel R, Shukla R, Bajpai A. Predictors of metabolic complications in obese Indian children and adolescents. Indian J Pediatr. 2021;88:252–6.
Article CAS PubMed Google Scholar
Libman I, Haynes A, Lyons S, et al. ISPAD clinical practice consensus guidelines 2022: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23:1160–74.
Shah AS, Zeitler PS, Wong J, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022;23:872–902.
Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.
Khadilkar VV, Khadilkar AV. Revised Indian Academy of Pediatrics 2015 growth charts for height, weight and body mass index for 5-18-year-old Indian children. Indian J Endocrinol Metab. 2015;19:470–6.
Article PubMed PubMed Central Google Scholar
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.
Article CAS PubMed PubMed Central Google Scholar
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2017;64:319–34.
Article PubMed PubMed Central Google Scholar
Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44:2438–44.
Article CAS PubMed PubMed Central Google Scholar
Hockett CW, Praveen PA, Ong TC, et al. Clinical profile at diagnosis with youth-onset type 1 and type 2 diabetes in two pediatric diabetes registries: SEARCH (United States) and YDR (India). Pediatr Diabetes. 2021;22:22–30.
TODAY Study Group, Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56.
Article PubMed Central Google Scholar
Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care. 2022;45:1833–40.
Article CAS PubMed PubMed Central Google Scholar
Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11:169–81.
Article CAS PubMed PubMed Central Google Scholar
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. NDA 022341/S-031, approval letter, 17 Jun 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022341Orig1s031ltr.pdf.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes. Accessed on 24 Jan 2024.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-class-medicines-treat-pediatric-type-2-diabetes. Accessed on 24 Jan 2024.
Sarathi V, Kolly A, Chaithanya HB, Dwarakanath CS. High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy. J Nat Sci Biol Med. 2017;8:60–3.
Article PubMed PubMed Central Google Scholar
Meerasa A, Dash S. Weighing in on type 2 diabetes remission. Diabetes Care. 2022;45:28–30.
Comments (0)